Swine Flu Vaccine Found To Give Broader Flu Protection - RedOrbit

RedOrbit

Swine Flu Vaccine Found To Give Broader Flu Protection RedOrbit The progress in the research, published in this week's edition of the Proceedings of the National Academy of Sciences, assists scientists in their work to create a pan-influenza vaccine that can activate cross-creative antibodies at high levels to ... Pandemic 2009 H1N1 vaccination produces antibodies against multiple flu strainsEurekAlert (press release) Vaccination against 2009 H1N1 protects against multiple strainsVaccine News Daily (blog) Flu `Holy Grail` comes closer to realityZee News Express.co.uk all 116 news articles »

Remedying Global Health R&D - AllAfrica.com

Remedying Global Health R&D AllAfrica.com But an MSF survey of drugs developed from 1975 to 2004 found that only 18 out of 1556 were for such diseases. "We have no model which would meet the need for new drugs in a sustainable way," the head of pharmaceutical company Novartis told ... and more »

Researchers aim to assemble the tree of life for all 2 million named species - Texas A&M University

Texas A&M University

Researchers aim to assemble the tree of life for all 2 million named species Texas A&M University Information about evolutionary relationships has helped scientists identify promising new medicines, develop hardier, higher-yielding crops, and fight infectious diseases such as HIV, anthrax and influenza. If evolutionary trees are so widely used, ...

MIDDLETON - Lucigen gets grant for influenza test - BizTimes.com (Milwaukee)

MIDDLETON - Lucigen gets grant for influenza test BizTimes.com (Milwaukee) Middleton-based Lucigen Corp. is getting a three-year, $2.8 million grant to develop a new kind of test for influenza. The Small Business Innovation Research grant is from the National Institutes of Health. Lucigen says it has discovered an enzyme that ... Lucigen receives grant to develop influenza screenVaccine News Daily (blog) all 2 news articles »

Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of ... - MarketWatch (press release)

Theraclone Sciences Announces Positive Top-line Data from a Phase 1 Trial of ... MarketWatch (press release) ... a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections. and more »